Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rolls-Royce expects 'mitigating actions' to offset tariff hit

(Sharecast News) - Rolls-Royce reported a "strong" start to the year and said that it expected to be able to offset the hit from US trade tariffs. In a trading update issued ahead of its AGM, the engineer's chief executive officer, Tufan Erginbilgic, said that the company was taking "mitigation actions" with respect to the tariffs.

It was also closely monitoring their potential indirect impact on economic growth and inflation.

"Good progress on our transformation and the actions we are taking give us confidence in our guidance for 2025 of £2.7bn-£2.9bn of underlying operating profit and £2.7bn-£2.9bn of free cash flow," he added.

All divisions were performing well, the engineer said, describing demand across the group's products as "strong".

Among other highlights, in Civil Aerospace, LTSA large engine flying hours were said to have reached 110% of their 2019 levels.

The company also announced that certification of the new HPT blade for its Trent 1000 engines, which would double the 'time on wing' of the engine, was expected in the coming weeks.

A further 30% improvement for time on wing for the Trent 1000 and 7000 engines was anticipated by the end of 2025.

Demand remained robust in Defence and in Power Systems the book-to-bill ratio stood at 1.5, helped by continued demand for back-up power generators for data centres.

Rolls Royce SMR meanwhile was looking forward to a decision on its tender by Great British Nuclear in June.

The company had thus far carried out £138m of share buybacks under its £1bn authorisation.

Shares of Rolls Royce were trading 2.42% higher as of 772.80p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.